Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (311-320 of 436) with videos related to

Pageof 44
Sort By:
Blood Advances|April 27, 2023
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantationNicholas J Short, Faustine Ong, Farhad Ravandi, et al.
Blood Cancer Journal|September 30, 2021
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangementsGhayas C Issa, Jabra Zarka, Koji Sasaki, et al.
American Journal of Hematology|July 17, 2024
Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemiaSanam Loghavi, Qing Wei, Farhad Ravandi, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of <i>TP53</i> alterations and venetoclax treatmentHussein A Abbas, Edward Ayoub, Hanxiao Sun, et al.
British Journal of Haematology|February 22, 2021
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemiaSanam Loghavi, Courtney D DiNardo, Ken Furudate, et al.
Cancer|June 25, 2021
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemiaKapil Saxena, Shelley M Herbrich, Naveen Pemmaraju, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 10, 2014
Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemiaNaveen Pemmaraju, Dhaval Shah, Hagop Kantarjian, et al.
Blood Cancer Discovery|April 14, 2026
Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trialJayastu Senapati, Hagop M Kantarjian, Edward Ayoub, et al.
The Lancet. Haematology|May 15, 2023
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trialElias Jabbour, Nicholas J Short, Jayastu Senapati, et al.
Cancer|June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageGeorgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
Pageof 44

Showing results (311-320 of 436) with videos related to

Sort By:
Pageof 44
Blood Advances|April 27, 2023
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantationNicholas J Short, Faustine Ong, Farhad Ravandi, et al.
Blood Cancer Journal|September 30, 2021
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangementsGhayas C Issa, Jabra Zarka, Koji Sasaki, et al.
American Journal of Hematology|July 17, 2024
Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemiaSanam Loghavi, Qing Wei, Farhad Ravandi, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of <i>TP53</i> alterations and venetoclax treatmentHussein A Abbas, Edward Ayoub, Hanxiao Sun, et al.
British Journal of Haematology|February 22, 2021
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemiaSanam Loghavi, Courtney D DiNardo, Ken Furudate, et al.
Cancer|June 25, 2021
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemiaKapil Saxena, Shelley M Herbrich, Naveen Pemmaraju, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 10, 2014
Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemiaNaveen Pemmaraju, Dhaval Shah, Hagop Kantarjian, et al.
Blood Cancer Discovery|April 14, 2026
Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trialJayastu Senapati, Hagop M Kantarjian, Edward Ayoub, et al.
The Lancet. Haematology|May 15, 2023
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trialElias Jabbour, Nicholas J Short, Jayastu Senapati, et al.
Cancer|June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageGeorgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
Pageof 44